Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

iShares MSCI ACWI ETF / Technical Analysis

<ul>
<li>With the MSCI ACWI (ACWI-US) approaching the top-end of our expected 2023 trading range at $93, we see limited upside from here, and we believe caution is warranted.</li>
<li>We want to remain overweight Europe and the UK, but we prefer to buy only on pullbacks.</li>
<li>The Hang Seng and MSCI China (MCHI-US) are both getting rejected at their important resistances discussed last week, and we would expect to see a basing process develop below resistance.</li>
</ul>


With the MSCI ACWI (ACWI-US) approaching the top-end of our expected 2023 trading range at $93, we see limited upside from here, and we believe caution is warranted.
We want to remain overweight Europe and the UK, but we prefer to buy only on pullbacks.
The Hang Seng and MSCI China (MCHI-US) are both getting rejected at their important resistances discussed last week, and we would expect to see a basing process develop below resistance.


Caution Warranted; ACWI-US At $93 Resistance; Buys in Communications, Staples, Materials, Financials

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analysed the earning revision of component stocks of CSI 300 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Wuliangye, China Life, SHANGHAI PUDONG DEVELOPMENT BANK, BYD, PING AN INSURANCE, CHONGQING ZHIFEI BIOLOGICAL PRODUCTS, CHINA EASTERN AIRLINES, GUANGZHOU AUTOMOBILE, Ping An Insurance.</li>
</ul>


We analysed the earning revision of component stocks of CSI 300 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Wuliangye, China Life, SHANGHAI PUDONG DEVELOPMENT BANK, BYD, PING AN INSURANCE, CHONGQING ZHIFEI BIOLOGICAL PRODUCTS, CHINA EASTERN AIRLINES, GUANGZHOU AUTOMOBILE, Ping An Insurance.


CSI 300 Index Earning Revision (Oct): Wuliangye, China Life, SPDB, BYD

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

Equity Capital Markets

LG Energy Solution / Equity Capital Markets

<ul>
<li>We take a look at the Asia Pacific IPO pipeline for 2022. This list has been compiled on a best effort basis from tracking company filings and other sources.</li>
<li>For readers who aren't familiar with our coverage, we aim to cover all IPOs and placements with a minimum deal size of US$100m across Asia-Pacific (ex A-shares), including China ADRs. </li>
<li>The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.</li>
</ul>


We take a look at the Asia Pacific IPO pipeline for 2022. This list has been compiled on a best effort basis from tracking company filings and other sources.
For readers who aren't familiar with our coverage, we aim to cover all IPOs and placements with a minimum deal size of US$100m across Asia-Pacific (ex A-shares), including China ADRs. 
The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.


APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

<p><a href="https://www.smartkarma.com/entities/lb-group-co-ltd" target="_blank" data-smartkarma-citation="entities:9175:1" rel="noopener">LB Group Co Ltd (002601 CH)</a> is looking to raise up to $1.5bn in its upcoming Hong Kong IPO. The deal will be run by CICC, CMBI, Guotai Junan, GF Securities.</p><p>LB Group is a titanium dioxide powder producer and as per Frost &amp; Sullivan (F&amp;S), is the world’s third largest and Asia’s and the PRC’s largest titanium dioxide powder producer in terms of production volume, sales volume and production capacity in 2020. As of the latest practicable date (25 Sept 2021), the firm operated seven production bases in five Provinces in the PRC. It’s products are mainly used as raw materials for coatings, plastics, paper and printing ink.</p>

LB Group Co Ltd (002601 CH) is looking to raise up to $1.5bn in its upcoming Hong Kong IPO. The deal will be run by CICC, CMBI, Guotai Junan, GF Securities.LB Group is a titanium dioxide powder producer and as per Frost &amp; Sullivan (F&amp;S), is the world’s third largest and Asia’s and the PRC’s largest titanium dioxide powder producer in terms of production volume, sales volume and production capacity in 2020. As of the latest practicable date (25 Sept 2021), the firm operated seven production bases in five Provinces in the PRC. It’s products are mainly used as raw materials for coatings, plastics, paper and printing ink.

China

LB Group Co., Ltd. produces and sells chemical products. The Company manufactures and sells titanium, zirconium fine powder materials, and other products. LB Group also exports chemical products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

LB Group Co Ltd (002601 CH)

Caution Warranted; ACWI-US At $93 Resistance; Buys in Communications, Staples, Materials, Financials

With the MSCI $ACWI approaching the top-end of our expected 2023 trading range at $93, we see limited upside from here and believe caution is...

Vermilion Research

CSI 300 Index Earning Revision (Oct): Wuliangye, China Life, SPDB, BYD

We analyzed CSI 300's consensus for Oct 2025 and highlighted changes of EPS in Wuliangye (000858 CH), China Life (601628 CH), SHANGHAI PUDONG...

Ke Yan, CFA, FRM

Aequitas 2022 Asia IPO Pipeline

We take a look at the Asia Pacific IPO pipeline for 2022. This list has been compiled on a best effort basis from tracking company filings and...

Sumeet Singh

LB Group Pre-IPO Tearsheet

LB Group Co Ltd (002601 CH) is looking to raise up to $1.5bn in its upcoming Hong Kong IPO. The deal will be run by CICC, CMBI, Guotai Junan, GF...

Clarence Chu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)